Just relax. Nothing has changed with the science, clinical trials or direction with ALXN. We all just have to be patient and wait. This is not like the "ole" stock market anymore and since the bubble broke, the recession started, major failures with other companies,and the "new" accounting practices of Arthur/Anderson, not many folks want to buy into companies that don't have anything to sell. We have a winner with this company, but it does take time and patience on our part. Two years down the road, you'll be glad you bought at these BLUE LIGHT special prices and wishing you had bought more.
The only large quantity of options outstanding are the Feb.25 calls (over 2,000) With very little volume on the buy side, the option writers may have concentrated on bringing the vaue of these otions way down all week.
BE PATIENT. If the company eventually gets FDA approval(s), we'll have a huge winner.
good point -- given the large quantity of outstanding Feb 25 calls, we probably should assume that the option writers will keep us at or below $25 when we get close to the feb options expiration, but why apply the selling pressure now? suppose ALXN moves above the Feb 25 strike price prior to expiration, wouldn't this be a better time for the option writers to take the price back down (eg, by selling short) to $25?